Ann: PAT-DX1 significantly improves survival in aggressive GBM, page-4

Heres the meat of it:

-------------------------------------------------------------------
Study overview and results
Yale School of Medicine used a highly aggressive human GBM tumour explant to generate brain
tumours in mice. The study then tested the effects of PAT-DX1 and low dose radiation on tumour
growth and mouse survival across four different treatment regimens:
• Control: Control vehicle delivered three times a week
• Low dose radiation: Control + a single low dose radiation treatment
• PAT-DX1: PAT-DX1 alone delivered three times a week
• Combination: PAT-DX1 + a single low dose radiation treatment

Figure 1: Reduction in tumour size relative to
control (week 2)


Figure 2: Survival benefit due to treatment


1A GBM tumour explant was used to inoculate the brains of mice and the tumour was imaged weekly.
Figure 1 shows that as a single agent, PAT-DX1 outperformed low dose radiation in tumour
suppression and extended survival. Further, when PAT-DX1 was used in combination with low dose
radiation, an even greater reduction in tumour size and survival was achieved.
Figure 1: Reduction in tumour size relative to
control (week 2)
Figure 2: Survival benefit due to treatment
Figure 1 shows that two weeks after initiation of treatment, low dose radiation, PAT-DX1, and the
combination reduced tumour size by 52%, 87%, and 93% compared to control, respectively.
Figure 2 shows that low dose radiation alone extended mouse survival by 24% (P=0.04), as a single
agent, PAT-DX1 extended survival by 41% (P=0.01), and PAT-DX1 used in combination with low dose
radiation extended survival by 71% (P=0.002). No toxicity associated with PAT-DX1 treatment was
observed.